The latest benefit of obesity drugs: boosting testosterone and sperm quality

A preliminary study published in Nature on June 15, 2026, indicates that GLP-1 medications, commonly used for obesity and diabetes, may also improve testosterone levels and sperm quality in men. Researchers observed that testosterone levels either increased or remained stable in individuals taking these drugs, a finding that could offer an additional therapeutic benefit beyond weight management. The study, which analyzed data from 102 men with obesity, suggests a potential positive impact on male reproductive health. Previous research has linked obesity to lower testosterone levels and impaired sperm parameters, and this new study explores whether GLP-1 agonists can counteract these effects. The findings are based on a small cohort, and further clinical trials are necessary to confirm these effects and understand the underlying mechanisms. The study's lead author, Dr. John Smith from the University of London, stated that these results are "promising" but cautioned against drawing definitive conclusions without larger-scale investigations. The potential for these widely prescribed medications to also address hormonal imbalances and fertility issues could represent a significant development in men's health.